drugset / Trial / NCT02462161
Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
Phase 1
Completed
24 enrolled
Wake Forest University Health Sciences
General Electric · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.
Timeline
- Start
- 2015-03-20
- Primary completion
- 2019-04-16
- Completion
- 2019-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin aspart | Protein / enzyme biologic | 20 iu | Intranasal |